ArticleNature metabolism2020
KRAS-regulated glutamine metabolism requires UCP2-mediated aspartate transport to support pancreatic cancer growth.
Abstract read
In one paragraph
Article in Nature metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 140 citations in OpenAlex.
- Glutamine Metabolism in Health and Diseases.MedComm · 2026Review
- CD90 Promotes Gastric Cancer Progression by Regulating SLC1A5-Mediated Glutamine Metabolism Through YY1.Cancer science · 2026Article
- A Structural Context for the Mechanisms of Uncoupling Protein 1 in Brown Fat Thermogenesis.Acta physiologica (Oxford, England) · 2026Review
- Targeting glutamine metabolism to modulate macrophage functions in the tumor microenvironment.Discover oncology · 2026Review
- Metabolic plasticity in pancreatic ductal adenocarcinoma progression and response to treatment.Molecular cancer · 2026Review
- SPINK2 silencing suppresses leukemic proliferation and restores myeloid commitment via MECOM downregulation in acute myeloid leukaemia.Cell death discovery · 2026Article
- PanMETAI - a high performance tabular foundation model for accurate pancreatic cancer diagnosis via NMR metabolomics.Nature communications · 2026Article
- Metabolic reprogramming in cancer: signaling pathways and therapeutic targets.Molecular cancer · 2026Review
- Context-dependent roles of UCP2 in cancer: functional heterogeneity, molecular mechanisms and translational perspectives.Frontiers in oncology · 2026Review
- Targeting Glutamine Metabolic Reprogramming in Pancreatic Cancer: Current Insights and Future Directions.Current cancer drug targets · 2026Review
- Deciphering Uncoupling Proteins in Cellular Homeostasis and Metabolic Health.International journal of biological sciences · 2026Review
- Combined ketone body and glutamine supplementation restores aerobic energy production in AGC1-deficient neuronal progenitors.Cell death & disease · 2025Article
- The SLC1A1/EAAT3 dicarboxylic amino acid transporter is an epigenetically dysregulated nutrient carrier that sustains oncogenic metabolic programs.Nature communications · 2025Article
- UCP2 Upregulates ACSL3 to Enhance Lipid Droplet Release from Acinar Cells and Modulates the Sirt1/Smad3 Pathway to Promote Macrophage-to-Myofibroblast Transition in Chronic Pancreatitis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Mito-Genipin, a Novel Mitochondria-Targeted Genipin Derivative Modulates Oxidative Stress and Inflammation in Macrophages.Antioxidants (Basel, Switzerland) · 2025Article
- Dysfunctional glycolysis-UCP2-fatty acid oxidation promotes CTLA4Molecular medicine (Cambridge, Mass.) · 2025Article
- Mitochondrial uncoupling, energy substrate utilization, and brown adipose tissue as therapeutic targets in cancer.npj metabolic health and disease · 2025Review
- RANBP9 and RANBP10 cooperate in regulating non-small cell lung cancer proliferation.Journal of experimental & clinical cancer research : CR · 2025Article
- Mechanistic Foundations of KRAS-Driven Tumor Ecosystems: Integrating Crosstalk among Immune, Metabolic, Microbial, and Stromal Microenvironment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- CC48 a new CB2R agonist/FAAH inhibitor dual drug blocks gastric cancer progression and overcomes paclitaxel resistance.Journal of experimental & clinical cancer research : CR · 2025Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 8 institutions in 4 countries.
Susanna Raho *Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.
Loredana Capobianco *Department of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy.
Rocco Malivindi *Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.ORCID http://orcid.org/0000-0002-8313-2492
Angelo Vozza *Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.ORCID http://orcid.org/0000-0002-2433-465X
Carmela PiazzollaDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.ORCID http://orcid.org/0000-0002-1931-9906
Francesco De LeonardisDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.ORCID http://orcid.org/0000-0002-6278-1565
Ruggiero GorgoglioneDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.
Pasquale ScarciaDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.ORCID http://orcid.org/0000-0001-6216-0411
Francesca PezzutoDepartment of Biological and Environmental Sciences and Technologies, University of Salento, Lecce, Italy.
Gennaro AgrimiDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.ORCID http://orcid.org/0000-0002-5219-4412
Simona N BarileDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.
Isabella PisanoDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.
Stephan J ReshkinDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.ORCID http://orcid.org/0000-0001-9757-5908
Maria R GrecoDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.
Rosa A CardoneDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.
Vittoria RagoDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.ORCID http://orcid.org/0000-0003-3971-7378
Yuan LiDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.ORCID http://orcid.org/0000-0002-4024-6174
Carlo M T MarobbioDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.
Wolfgang SommergruberBoehringer Ingelheim RCV GmbH & Co KG, Vienna, Austria.
Christopher L RileyDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Francesco M LasorsaDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.
Edward MillsDivision of Pharmacy and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, USA.
Maria C VeglianteHematology and Cell Therapy Unit, Istituto di Ricovero e Cura a Carattere scientifico-Istituto Tumori 'Giovanni Paolo II', Bari, Italy.ORCID http://orcid.org/0000-0002-3165-1768
Giuseppe E De BenedettoDipartimento Beni Culturali, University of Salento, Lecce, Italy.ORCID http://orcid.org/0000-0002-0832-5470
Deborah FratantonioDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.ORCID http://orcid.org/0000-0003-4835-0571
Luigi PalmieriDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy.
Vincenza DolceDepartment of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy. vincenza.dolce@unical.it.ORCID http://orcid.org/0000-0003-2966-4866
Giuseppe FiermonteDepartment of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, Bari, Italy. giuseppe.fiermonte@uniba.it.ORCID http://orcid.org/0000-0002-6764-9395
University of Bari Aldo Moro · ITInstitute of Biomembranes, Bioenergetics and Molecular Biotechnologies · ITUniversity of Calabria · ITUniversity of Salento · ITAustin College · USBoehringer Ingelheim (Austria) · ATDana-Farber Cancer Institute · USIstituto Tumori Bari · IT
Funding
Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) IG 2014 Id.15404Ministero dell'Istruzione, dell'Università e della Ricerca (Ministry of Education, University and Research) 2017PAB8EM_002
Abstract
The oncogenic KRAS mutation has a critical role in the initiation of human pancreatic ductal adenocarcinoma (PDAC) since it rewires glutamine metabolism to increase reduced nicotinamide adenine dinucleotide phosphate (NADPH) production, balancing cellular redox homeostasis with macromolecular synthesis
Indexed as
AnimalsAspartic AcidBiological Transport, ActiveCarcinoma, Pancreatic DuctalCell Line, TumorCytosolFemaleGlutamineHumansMiceMice, SCIDMitochondriaNADPOxidation-ReductionPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Aspartic AcidGlutamineKRAS protein, humanNADPProto-Oncogene Proteins p21(ras)Reactive Oxygen SpeciesUCP2 protein, humanUncoupling Protein 2
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.